$16.9725
-0.0275[-0.16%]
Last update: 11:08AM Get Real Time Here
Privia Health Gr
(NASDAQ:PRVA)Privia Health Gr Stock (NASDAQ:PRVA), Analyst Ratings, Price Targets, Predictions
Privia Health Group Inc has a consensus price target of $32.96, established from looking at the 56 latest analyst ratings. The last 3 analyst ratings were released from Truist Securities, Canaccord Genuity, and Stifel on May 15, 2024, May 10, 2024, and May 1, 2024. With an average price target of $24.67 between Truist Securities, Canaccord Genuity, and Stifel, there's an implied 45.33% upside for Privia Health Group Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Canaccord Genuity
Stifel
Citigroup
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Privia Health Gr
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/15/2024 | Buy Now | 41.41% | Truist Securities | Jailendra Singh | $28 → $24 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 53.19% | Canaccord Genuity | Richard Close | $37 → $26 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | 41.41% | Stifel | Craig Jones | $28 → $24 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | 47.3% | Citigroup | Daniel Grosslight | → $25 | Initiates | → Buy | Get Alert |
| 03/19/2024 | Buy Now | 118% | Canaccord Genuity | Richard Close | $41 → $37 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | 76.76% | JP Morgan | Lisa Gill | $38 → $30 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 29.62% | Barclays | Andrew Mok | → $22 | Initiates | → Equal-Weight | Get Alert |
| 03/01/2024 | Buy Now | 70.86% | UBS | Andrew Mok | $31 → $29 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 53.19% | TD Cowen | Gary Taylor | $30 → $26 | Maintains | Outperform | Get Alert |
| 02/29/2024 | Buy Now | 64.97% | Truist Securities | Jailendra Singh | $32 → $28 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 47.3% | Evercore ISI Group | Elizabeth Anderson | $26 → $25 | Maintains | Outperform | Get Alert |
| 02/22/2024 | Buy Now | 23.73% | B of A Securities | Adam Ron | $27 → $21 | Downgrade | Buy → Neutral | Get Alert |
| 12/06/2023 | Buy Now | 59.08% | JMP Securities | Constantine Davides | → $27 | Initiates | → Market Outperform | Get Alert |
| 11/17/2023 | Buy Now | 123.89% | JP Morgan | Lisa Gill | $43 → $38 | Maintains | Overweight | Get Alert |
| 08/18/2023 | Buy Now | 88.54% | UBS | Andrew Mok | $35 → $32 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 106.22% | TD Cowen | Gary Taylor | $44 → $35 | Maintains | Outperform | Get Alert |
| 06/22/2023 | Buy Now | 141.57% | Credit Suisse | Jonathan Yon | → $41 | Reiterates | Outperform → Outperform | Get Alert |
| 06/13/2023 | Buy Now | 100.32% | Evercore ISI Group | Elizabeth Anderson | → $34 | Initiates | → Outperform | Get Alert |
| 05/08/2023 | Buy Now | 141.57% | Credit Suisse | Jonathan Yon | → $41 | Reiterates | → Outperform | Get Alert |
| 04/12/2023 | Buy Now | 94.43% | Stephens & Co. | Jeff Garro | → $33 | Initiates | → Overweight | Get Alert |
| 03/10/2023 | Buy Now | 112.11% | RBC Capital | Sean Dodge | → $36 | Initiates | → Outperform | Get Alert |
| 03/07/2023 | Buy Now | 141.57% | Credit Suisse | Jonathan Yong | → $41 | Reiterates | → Outperform | Get Alert |
| 02/03/2023 | Buy Now | 88.54% | Goldman Sachs | Jamie Perse | → $32 | Initiates | → Buy | Get Alert |
| 12/09/2022 | Buy Now | 64.97% | Stifel | Craig Jones | → $28 | Initiates | → Buy | Get Alert |
| 12/08/2022 | Buy Now | 76.76% | UBS | Andrew Mok | → $30 | Initiates | → Buy | Get Alert |
| 11/11/2022 | Buy Now | 153.35% | Canaccord Genuity | Richard Close | $50 → $43 | Maintains | Buy | Get Alert |
| 11/11/2022 | Buy Now | 129.78% | SVB Leerink | Whit Mayo | $46 → $39 | Maintains | Outperform | Get Alert |
| 09/07/2022 | Buy Now | 218.16% | Truist Securities | Jailendra Singh | $48 → $54 | Assumes | → Buy | Get Alert |
| 08/25/2022 | Buy Now | 194.59% | Canaccord Genuity | Richard Close | $45 → $50 | Maintains | Buy | Get Alert |
| 08/12/2022 | Buy Now | 182.81% | Truist Securities | David Macdonald | $40 → $48 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Privia Health Gr (PRVA)?
The latest price target for Privia Health Gr (NASDAQ: PRVA) was reported by Truist Securities on May 15, 2024. The analyst firm set a price target for $24.00 expecting PRVA to rise to within 12 months (a possible 41.41% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Privia Health Gr (PRVA)?
The latest analyst rating for Privia Health Gr (NASDAQ: PRVA) was provided by Truist Securities, and Privia Health Gr maintained their buy rating.
When was the last upgrade for Privia Health Gr (PRVA)?
The last upgrade for Privia Health Group Inc happened on February 22, 2022 when Cowen & Co. raised their price target to $35. Cowen & Co. previously had a market perform for Privia Health Group Inc.
When was the last downgrade for Privia Health Gr (PRVA)?
The last downgrade for Privia Health Group Inc happened on February 22, 2024 when B of A Securities changed their price target from $27 to $21 for Privia Health Group Inc.
When is the next analyst rating going to be posted or updated for Privia Health Gr (PRVA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Privia Health Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Privia Health Gr was filed on May 15, 2024 so you should expect the next rating to be made available sometime around May 15, 2025.
Is the Analyst Rating Privia Health Gr (PRVA) correct?
While ratings are subjective and will change, the latest Privia Health Gr (PRVA) rating was a maintained with a price target of $28.00 to $24.00. The current price Privia Health Gr (PRVA) is trading at is $16.97, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.